Charles River Laboratories Set to Announce Q4 Earnings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CRL?
Source: seekingalpha
- Earnings Announcement Date: Charles River Laboratories is set to release its Q4 2023 earnings report on February 18 before market open, with consensus EPS estimated at $2.35, reflecting an 11.7% year-over-year decline, and revenue expected at $986.98 million, down 1.3% year-over-year, indicating potential revenue challenges ahead.
- Historical Performance: Over the past two years, CRL has consistently beaten EPS and revenue estimates 100% of the time, showcasing strong financial stability and market confidence, which could positively influence investor sentiment leading up to the earnings release.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, reflecting mixed market perceptions regarding the company's future performance, which may impact investor decisions.
- Executive Change: The appointment of Birgit Girshick as CEO, succeeding the retiring James Foster, could influence the company's strategic direction and market confidence, particularly at this critical juncture before the earnings report.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 161.350
Low
185.00
Averages
226.70
High
265.00
Current: 161.350
Low
185.00
Averages
226.70
High
265.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Charles River Laboratories Set to Announce Q4 Earnings
- Earnings Announcement Date: Charles River Laboratories is set to release its Q4 2023 earnings report on February 18 before market open, with consensus EPS estimated at $2.35, reflecting an 11.7% year-over-year decline, and revenue expected at $986.98 million, down 1.3% year-over-year, indicating potential revenue challenges ahead.
- Historical Performance: Over the past two years, CRL has consistently beaten EPS and revenue estimates 100% of the time, showcasing strong financial stability and market confidence, which could positively influence investor sentiment leading up to the earnings release.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, reflecting mixed market perceptions regarding the company's future performance, which may impact investor decisions.
- Executive Change: The appointment of Birgit Girshick as CEO, succeeding the retiring James Foster, could influence the company's strategic direction and market confidence, particularly at this critical juncture before the earnings report.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Charles River Laboratories Named Among Top Mid-Cap AI Stocks
- Price Target Increase: Analyst Charles Rhyee at TD Cowen raised the price target for Charles River Laboratories from $197 to $251 on January 22, indicating a potential upside of 38.49%, reflecting strong market confidence in the company's future performance.
- Strong Earnings Outlook: In its Q4 earnings preview, TD Cowen expressed optimism about solid quarterly results for Charles River, suggesting that the 2026 guidance could serve as a pivotal moment for operating conditions, providing investors with clearer short-term insights.
- Gene Therapy Collaboration: On January 21, Charles River announced a new gene therapy collaboration with Gazi University Faculty of Medicine, providing plasmid DNA for AAV production, aimed at advancing research on a rare inherited disorder, showcasing the company's proactive approach in innovative fields.
- Global Service Network: Charles River Laboratories offers non-clinical development, drug discovery, and safety testing services across the U.S., Asia-Pacific, Europe, and Canada, demonstrating its extensive influence and business diversity in the global market.
See More
Risks and Rewards of Selling Put Options
- Options Selling Mechanism: Selling put options does not provide investors with the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, and if the stock price does not fall to the strike price, the seller only collects the premium.
- Yield Analysis: If Charles River Laboratories' shares do not decline by 6.8%, the only upside for the seller is the 18.8% annualized return, highlighting the asymmetry between risk and reward in options trading.
- Volatility Consideration: With a trailing twelve-month volatility of 58% for Charles River Laboratories, combining this with fundamental analysis can help investors assess whether selling puts at the $150 strike price is worthwhile, especially with the current stock price at $161.49.
- Market Trading Dynamics: During mid-afternoon trading on Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Charles River Laboratories to Release Q4 2025 Results and 2026 Guidance on February 18
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q4 and full-year 2025 financial results along with 2026 guidance on February 18, 2025, before market open, aiming to provide investors with a clear outlook for the future.
- Conference Call Details: A conference call is scheduled for February 18, 2025, at 8:30 a.m. ET to discuss the financial results and guidance, enhancing communication and transparency with investors.
- Live Webcast Opportunity: Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the company's website, ensuring timely access to key information for all stakeholders.
- Replay Access: Following the call, a replay will be available on the same website, further improving the accessibility and transparency of information for investors.
See More
Charles River Laboratories Under Investigation, Revenue Growth Expected to Decline by 400 Basis Points
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti announces that Kahn Swick & Foti, LLC is investigating Charles River Laboratories for potential breaches of fiduciary duties to shareholders.
- Legal Action: Charles River and its executives are facing a securities class action lawsuit for failing to disclose material information, which could further impact the company's reputation and stock price.
- Revenue Growth Decline: The company disclosed in February 2023 that it suspended shipments of non-human primates from Cambodia due to a subpoena from the U.S. Department of Justice, leading to an expected revenue growth decline of 200 to 400 basis points, directly affecting annual financial performance.
- Compliance Risks: Kahn Swick & Foti's investigation will assess whether Charles River violated state or federal laws, and if confirmed, could lead to more severe legal consequences and financial losses.
See More
Charles River Laboratories Set to Announce Q4 Earnings
- Earnings Announcement Date: Charles River Laboratories is set to release its Q4 2023 earnings report on February 18 before market open, with consensus EPS estimated at $2.35, reflecting an 11.7% year-over-year decline, and revenue expected at $986.98 million, down 1.3% year-over-year, indicating potential revenue challenges ahead.
- Historical Performance: Over the past two years, CRL has consistently beaten EPS and revenue estimates 100% of the time, showcasing strong financial stability and market confidence, which could positively influence investor sentiment leading up to the earnings release.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates experienced one upward and one downward revision, reflecting mixed market perceptions regarding the company's future performance, which may impact investor decisions.
- Executive Change: The appointment of Birgit Girshick as CEO, succeeding the retiring James Foster, could influence the company's strategic direction and market confidence, particularly at this critical juncture before the earnings report.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
Charles River Laboratories Named Among Top Mid-Cap AI Stocks
- Price Target Increase: Analyst Charles Rhyee at TD Cowen raised the price target for Charles River Laboratories from $197 to $251 on January 22, indicating a potential upside of 38.49%, reflecting strong market confidence in the company's future performance.
- Strong Earnings Outlook: In its Q4 earnings preview, TD Cowen expressed optimism about solid quarterly results for Charles River, suggesting that the 2026 guidance could serve as a pivotal moment for operating conditions, providing investors with clearer short-term insights.
- Gene Therapy Collaboration: On January 21, Charles River announced a new gene therapy collaboration with Gazi University Faculty of Medicine, providing plasmid DNA for AAV production, aimed at advancing research on a rare inherited disorder, showcasing the company's proactive approach in innovative fields.
- Global Service Network: Charles River Laboratories offers non-clinical development, drug discovery, and safety testing services across the U.S., Asia-Pacific, Europe, and Canada, demonstrating its extensive influence and business diversity in the global market.
See More
Risks and Rewards of Selling Put Options
- Options Selling Mechanism: Selling put options does not provide investors with the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, and if the stock price does not fall to the strike price, the seller only collects the premium.
- Yield Analysis: If Charles River Laboratories' shares do not decline by 6.8%, the only upside for the seller is the 18.8% annualized return, highlighting the asymmetry between risk and reward in options trading.
- Volatility Consideration: With a trailing twelve-month volatility of 58% for Charles River Laboratories, combining this with fundamental analysis can help investors assess whether selling puts at the $150 strike price is worthwhile, especially with the current stock price at $161.49.
- Market Trading Dynamics: During mid-afternoon trading on Friday, the put volume among S&P 500 components reached 1.33 million contracts, matching call volume, indicating a higher demand for puts than the long-term median, reflecting investor expectations of market volatility.
See More
Charles River Laboratories to Release Q4 2025 Results and 2026 Guidance on February 18
- Earnings Release Schedule: Charles River Laboratories is set to announce its Q4 and full-year 2025 financial results along with 2026 guidance on February 18, 2025, before market open, aiming to provide investors with a clear outlook for the future.
- Conference Call Details: A conference call is scheduled for February 18, 2025, at 8:30 a.m. ET to discuss the financial results and guidance, enhancing communication and transparency with investors.
- Live Webcast Opportunity: Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the company's website, ensuring timely access to key information for all stakeholders.
- Replay Access: Following the call, a replay will be available on the same website, further improving the accessibility and transparency of information for investors.
See More
Charles River Laboratories Under Investigation, Revenue Growth Expected to Decline by 400 Basis Points
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti announces that Kahn Swick & Foti, LLC is investigating Charles River Laboratories for potential breaches of fiduciary duties to shareholders.
- Legal Action: Charles River and its executives are facing a securities class action lawsuit for failing to disclose material information, which could further impact the company's reputation and stock price.
- Revenue Growth Decline: The company disclosed in February 2023 that it suspended shipments of non-human primates from Cambodia due to a subpoena from the U.S. Department of Justice, leading to an expected revenue growth decline of 200 to 400 basis points, directly affecting annual financial performance.
- Compliance Risks: Kahn Swick & Foti's investigation will assess whether Charles River violated state or federal laws, and if confirmed, could lead to more severe legal consequences and financial losses.
See More
